From: Pathophysiology and therapeutic potential of cardiac fibrosis
Trial | CADUCEUS | SCIPIO | ||
---|---|---|---|---|
Inclusion criteria | Patient characteristics | Previous MI | Previous MI and CABG | |
EF (%) | 25–45 | ≤40 | ||
No. of patients | Total | 25 | 23 | |
Cell therapy group | 17 | 16 | ||
Control group | 8 | 7 | ||
Cell therapy | Type of cardiac stem cells | Cardiosphere-derived cells | c-kit-positive CPCs | |
Dose of injected cells | 12.5–25 million | 0.5–1 million | ||
Delivery method | Intracoronary infusion | Intracoronary infusion | ||
Timing of delivery | 1.5–3 months after MI | 4 ± 1 months after CABG | ||
Outcomes | EF (%); baseline/follow-up | Cell therapy | 42.4/48.2 (1Â year) | 30.3/38.5 (4 months) |
Control | 42.5/48.1 (1Â year) | 30.1/30.2 (4 months) | ||
Scar size (%LV or g); baseline/follow-up | Cell therapy | 23.8/12.9 (1Â year) (%LV) | 32.6/22.8 (1Â year) (g) | |
Control | 22.4/20.3 (1Â year) (%LV) | N/A | ||
References | Â | Â | [53] |